Pentaglobin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Pentaglobin
- Accession Number
- DB15865
- Description
Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations.1 It is comprised of immunoglobulin G (IgG) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).3
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- IgM-enriched immunoglobulins
- IVIgGM
- External IDs
- Pentaglobin
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
Pentaglobin has potential antibacterial and immunomodulatory properties where, compared to immunoglobulin treatments without IgM, pentaglobin may have an increased ability to eliminate infectious pathogens . The IgM in the preparation plays a role in complement activation and neutralization of bacterial endo- and exotoxins.3 Pentaglobin is used as an adjuvant in treatment of severe bacterial infections while it is also investigated against peritonitis, sepsis, and COVID-19.2
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Neilson AR, Burchardi H, Schneider H: Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005 Sep;20(3):239-49. doi: 10.1016/j.jcrc.2005.03.003. [PubMed:16253792]
- Vaira M, Scuderi S, Costamagna D, Barone R, De Simone M: [Use of pentaglobin in the treatment of sepsis in the patient undergoing intraperitoneal hyperthermic chemotherapy]. Tumori. 2003 Jul-Aug;89(4 Suppl):296-7. [PubMed:12903625]
- National Cancer Institute: IgM-enriched Immunoglobulins (CUI CL563000) [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Neonatal Sepsis / Very Low Birth Weight Baby 1 4 Unknown Status Treatment Sepsis of the Newborn 1 3 Not Yet Recruiting Prevention Infant, Newborn, Diseases / Inflammatory Reaction / Neonatal Sepsis, Early-Onset / Very Low Birth Weight Infant 1 3 Not Yet Recruiting Treatment Hypoglobulinemia / Sepsis / Shock, Septic 1 2 Completed Treatment Severe Sepsis / Shock, Septic 1 2 Recruiting Treatment Shock, Septic 1 2 Suspended Treatment Peritonitis / Sepsis 1 2, 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 Not Available Completed Not Available Respiratory Distress Syndrome, Adult / Shock, Septic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 21, 2020 13:56 / Updated on September 22, 2020 13:00